Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2022

Revenue Recognition

Schedule of disaggregation of revenue

	Year Ended December 31,
	2022		2021		2020
Collaborative revenue
CSL Vifor (KORSUVA injection profit sharing)	$	16,572	$	—	$	—
Maruishi		—		706		—
Total collaborative revenue	$	16,572	$	706	$	—
License and milestone fees
CSL Vifor*		15,000		20,031		133,813
Maruishi		—		1,192		—
CKDP		—		—		626
Total license and milestone fees	$	15,000	$	21,223	$	134,439
Commercial supply revenue
CSL Vifor* (KORSUVA injection)	$	10,223	$	701	$	—
Total commercial supply revenue	$	10,223	$	701	$	—
Royalty revenue
CSL Vifor (Kapruvia ex U.S.)	$	72	$	—	$	—
Total royalty revenue	$	72	$	—	$	—
Clinical compound revenue
CSL Vifor* (difelikefalin injection)	$	—	$	361	$	115
Maruishi		—		37		528
Total clinical compound revenue	$	—	$	398	$	643

_____________________________

* Includes amounts earned from Vifor Fresenius Medical Care Renal Pharma Ltd. and Vifor International prior to Vifor International’s assignment of its rights and obligations to Vifor Fresenius Medical Care Renal Pharma Ltd. in May 2022.